Comparing two methods of magnesium sulphate administration to prevent seizures in women with eclampsia
Frequency of Recurrence of Seizures With Intravenous Versus Intramuscular Magnesium Sulphate in Women With Eclampsia
This study is testing whether giving magnesium sulphate through an IV is better than giving it through a shot to help prevent seizures in women with eclampsia.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Nishtar Medical University Academic / other |
| Locations | 1 site (Multan, Punjab) |
| Trial ID | NCT06997575 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to determine whether intravenous (IV) magnesium sulphate is more effective than intramuscular (IM) magnesium sulphate in preventing recurrent seizures in women diagnosed with eclampsia. Participants will be randomly assigned to receive either an IV regimen or a combined IV-plus-IM regimen of magnesium sulphate. The study will monitor the frequency of seizure recurrence in both groups to assess the efficacy of the different administration methods. The trial focuses on women aged 18-45 who are admitted to the labor room due to eclampsia.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18-45 who are experiencing eclampsia during labor.
Not a fit: Patients with intracranial bleeding or those who have already received magnesium sulphate or other anticonvulsants prior to hospital admission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for preventing seizures in women with eclampsia, enhancing maternal and fetal outcomes.
How similar studies have performed: Previous studies have indicated the effectiveness of magnesium sulphate in managing eclampsia, but this specific comparison of IV versus IM administration is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted in labor room due to eclampsia (new onset of grand mal seizure activity and/or unexplained coma during pregnancy) Exclusion Criteria: * Patients with intracranial bleeding (on CT-scan) * Already received MgSO4, phenytoin and diazepam before attending the hospital
Where this trial is running
Multan, Punjab
- Nishtar Medical University & Hospital — Multan, Punjab, Pakistan (Recruiting)
Study contacts
- Study coordinator: Laraib Irshad Principal Investigator, MBBS
- Email: laraibirshad1002@gmail.com
- Phone: +92 03179984660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.